{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T04:46:01Z","timestamp":1780634761642,"version":"3.54.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s40259-024-00683-0","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T15:07:21Z","timestamp":1729004841000},"page":"831-844","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Advanced Therapy Medicinal Products: Availability, Access and Expenditure in Italy"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5999-1230","authenticated-orcid":false,"given":"Pia","family":"Rivetti di Val Cervo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Alessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilena","family":"Lastella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"La Greca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6889-8484","authenticated-orcid":false,"given":"Francesco","family":"Trotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,15]]},"reference":[{"issue":"10","key":"683_CR1","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1038\/MT.2012.194","volume":"20","author":"S Yl\u00e4-Herttuala","year":"2012","unstructured":"Yl\u00e4-Herttuala S. Endgame: glybera finally recommended for approval as the first gene therapy drug in the European Union. Mol Ther. 2012;20(10):1831. https:\/\/doi.org\/10.1038\/MT.2012.194.","journal-title":"Mol Ther"},{"issue":"September","key":"683_CR2","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.omtm.2020.05.035","volume":"18","author":"M Elsallab","year":"2020","unstructured":"Elsallab M, Bravery CA, Kurtz A, Abou-El-Enein M. Mitigating deficiencies in evidence during regulatory assessments of advanced therapies: a comparative study with other biologicals. Mol Ther Methods Clin Dev. 2020;18(September):269\u201379. https:\/\/doi.org\/10.1016\/j.omtm.2020.05.035.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"683_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/nrd.2018.200","volume":"18","author":"L Barkholt","year":"2018","unstructured":"Barkholt L, Voltz-Girolt C, Raine J, Salmonson T, Sch\u00fcssler-Lenz M. European regulatory experience with advanced therapy medicinal products. Nat Rev Drug Discov. 2018;18(1):8\u20139. https:\/\/doi.org\/10.1038\/nrd.2018.200.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"683_CR4","doi-asserted-by":"publisher","first-page":"759","DOI":"10.18609\/cgti.2019.088","volume":"5","author":"CA Bravery","year":"2019","unstructured":"Bravery CA, Ball O, Robinson S. EU market authorisation strategy: lessons from the first 22 ATMP submitted to the EMA. Cell Gene Ther Insights. 2019;5(6):759\u201391. https:\/\/doi.org\/10.18609\/cgti.2019.088.","journal-title":"Cell Gene Ther Insights"},{"key":"683_CR5","doi-asserted-by":"publisher","unstructured":"Gribben J, Chabannon C, Yakoub-agha I, Einsele H. The EBMT\/EHA CAR-T Cell Handbook. 2022. https:\/\/doi.org\/10.1007\/978-3-030-94353-0.","DOI":"10.1007\/978-3-030-94353-0"},{"key":"683_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/IJERPH20053830","author":"E Foglia","year":"2023","unstructured":"Foglia E, et al. Multidimensional Results and Reflections on CAR-T: The Italian Evidence. Int J Environ Res Public Health. 2023. https:\/\/doi.org\/10.3390\/IJERPH20053830.","journal-title":"Int J Environ Res Public Health"},{"issue":"9","key":"683_CR7","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1089\/hum.2015.29010.trf","volume":"26","author":"TR Flotte","year":"2015","unstructured":"Flotte TR. Ethical implications of the cost of molecularly targeted therapies. Hum Gene Ther. 2015;26(9):573\u20134. https:\/\/doi.org\/10.1089\/hum.2015.29010.trf.","journal-title":"Hum Gene Ther"},{"issue":"1","key":"683_CR8","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jval.2022.07.004","volume":"26","author":"A Olry de Labry-Lima","year":"2023","unstructured":"Olry de Labry-Lima A, Ponce-Polo A, Garc\u00eda-Moch\u00f3n L, Ortega-Ortega M, P\u00e9rez-Troncoso D, Epstein D. Challenges for economic evaluations of advanced therapy medicinal products: a systematic review. Value Heal. 2023;26(1):138\u201350. https:\/\/doi.org\/10.1016\/j.jval.2022.07.004.","journal-title":"Value Heal"},{"issue":"3","key":"683_CR9","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jval.2021.09.012","volume":"25","author":"RMT ten Ham","year":"2022","unstructured":"ten Ham RMT, et al. Key considerations in the health technology assessment of advanced therapy medicinal products in Scotland, The Netherlands, and England. Value Heal. 2022;25(3):390\u20139. https:\/\/doi.org\/10.1016\/j.jval.2021.09.012.","journal-title":"Value Heal"},{"issue":"October","key":"683_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2021.755052","volume":"12","author":"L Gozzo","year":"2021","unstructured":"Gozzo L, et al. Health technology assessment of advanced therapy medicinal products: comparison among 3 European countries. Front Pharmacol. 2021;12(October):1\u20139. https:\/\/doi.org\/10.3389\/fphar.2021.755052.","journal-title":"Front Pharmacol"},{"key":"683_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-023-09494-5","author":"M Drummond","year":"2023","unstructured":"Drummond M, et al. How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy? BMC Health Serv Res. 2023. https:\/\/doi.org\/10.1186\/s12913-023-09494-5.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"683_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40545-021-00311-0","volume":"14","author":"V Ronco","year":"2021","unstructured":"Ronco V, Dilecce M, Lanati E, Canonico PL, Jommi C. Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations? J Pharm Policy Pract. 2021;14(1):1\u201311. https:\/\/doi.org\/10.1186\/s40545-021-00311-0.","journal-title":"J Pharm Policy Pract"},{"key":"683_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1199500","author":"JC Rejon-Parrilla","year":"2023","unstructured":"Rejon-Parrilla JC, Espin J, Garner S, Kniazkov S, Epstein D. Pricing and reimbursement mechanisms for advanced therapy medicinal products in 20 countries. Front Pharmacol. 2023. https:\/\/doi.org\/10.3389\/fphar.2023.1199500.","journal-title":"Front Pharmacol"},{"issue":"6","key":"683_CR14","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jval.2022.12.014","volume":"26","author":"C Iglesias-L\u00f3pez","year":"2023","unstructured":"Iglesias-L\u00f3pez C, Agust\u00ed A, Vallano A, Obach M. Financing and reimbursement of approved advanced therapies in several European countries. Value Heal. 2023;26(6):841\u201353. https:\/\/doi.org\/10.1016\/j.jval.2022.12.014.","journal-title":"Value Heal."},{"issue":"4","key":"683_CR15","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jval.2019.12.008","volume":"23","author":"M Dabbous","year":"2020","unstructured":"Dabbous M, Chachoua L, Caban A, Toumi M. Managed entry agreements: policy analysis from the European perspective. Value Heal. 2020;23(4):425\u201333. https:\/\/doi.org\/10.1016\/j.jval.2019.12.008.","journal-title":"Value Heal"},{"issue":"6","key":"683_CR16","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/nbt0617-491","volume":"35","author":"M Senior","year":"2017","unstructured":"Senior M. After Glybera\u2019s withdrawal, what\u2019s next for gene therapy? Nat Biotechnol. 2017;35(6):491\u20132. https:\/\/doi.org\/10.1038\/nbt0617-491.","journal-title":"Nat Biotechnol"},{"key":"683_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/D43978-023-00145-1","author":"MC Valsecchi","year":"2023","unstructured":"Valsecchi MC. Rescue of an orphan drug points to a new model for therapies for rare diseases. Nat Italy. 2023. https:\/\/doi.org\/10.1038\/D43978-023-00145-1.","journal-title":"Nat Italy"},{"issue":"8","key":"683_CR18","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.stem.2023.07.004","volume":"30","author":"A Izeta","year":"2023","unstructured":"Izeta A, Cuende N. Regulation of advanced therapies in Europe: are we on the right track? Cell Stem Cell. 2023;30(8):1013\u20136. https:\/\/doi.org\/10.1016\/j.stem.2023.07.004.","journal-title":"Cell Stem Cell"},{"key":"683_CR19","unstructured":"Gazzetta Ufficiale della Repubblica italiana. https:\/\/www.gazzettaufficiale.it\/ricerca\/atto\/serie_generale\/originario?reset=true&normativi=false"},{"key":"683_CR20","unstructured":"Union Register of Medicinal Products. https:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/reg_hum_atc.htm"},{"key":"683_CR21","unstructured":"AIFA. https:\/\/www.aifa.gov.it\/en\/registri-farmaci-sottoposti-a-monitoraggio. Registries. https:\/\/www.aifa.gov.it\/en\/registri-farmaci-sottoposti-a-monitoraggio"},{"key":"683_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.699466","author":"E Xoxi","year":"2021","unstructured":"Xoxi E, Facey KM, Cicchetti A. The evolution of AIFA registries to support managed entry agreements for orphan medicinal products in Italy. Front Pharmacol. 2021. https:\/\/doi.org\/10.3389\/fphar.2021.699466.","journal-title":"Front Pharmacol."},{"issue":"5","key":"683_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103549","volume":"28","author":"GC Wilkins","year":"2023","unstructured":"Wilkins GC, Lanyi K, Inskip A, Ogunbayo OJ, Brhlikova P, Craig D. A pipeline analysis of advanced therapy medicinal products. Drug Discov Today. 2023;28(5): 103549. https:\/\/doi.org\/10.1016\/j.drudis.2023.103549.","journal-title":"Drug Discov Today"},{"key":"683_CR24","unstructured":"European Medicines Agency EMA. Zalmoxis Withdrawal MA. 2014;44(September): 587151. [Online]. Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zalmoxis."},{"key":"683_CR25","unstructured":"European Medicines Agency EMA. Glybera expiry of the marketing authorisation in the European Union. Eur Med Agency. 2017;44(October):713863. [Online]. Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/glybera."},{"key":"683_CR26","unstructured":"European Medicines Agency EMA. Provenge Withdrawal MA. 2015;44(May):303072. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/provenge."},{"key":"683_CR27","unstructured":"European Medicines Agency EMA. Zynteglo Withdrawal MA. 2014;44(September): 192892. [Online]. Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zynteglo."},{"key":"683_CR28","unstructured":"European Medicines Agency EMA. MACI Expiry of the marketing authorisation in the European Union. 2018;44(July):457300. [Online]. Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/maci."},{"key":"683_CR29","unstructured":"European Medicines Agency EMA. ChondroCelect Withdrawal MA. 2016;44(July): 6000. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/chondrocelect"},{"issue":"June","key":"683_CR30","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.omtm.2019.01.010","volume":"13","author":"G Detela","year":"2019","unstructured":"Detela G, Lodge A. EU regulatory pathways for ATMPs: standard, accelerated and adaptive pathways to marketing authorisation. Mol Ther Methods Clin Dev. 2019;13(June):205\u201332. https:\/\/doi.org\/10.1016\/j.omtm.2019.01.010.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"2","key":"683_CR31","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.drudis.2017.10.012","volume":"23","author":"MP Hofer","year":"2018","unstructured":"Hofer MP, et al. Marketing authorisation of orphan medicines in Europe from 2000 to 2013. Drug Discov Today. 2018;23(2):424\u201333. https:\/\/doi.org\/10.1016\/j.drudis.2017.10.012.","journal-title":"Drug Discov Today"},{"key":"683_CR32","doi-asserted-by":"publisher","unstructured":"A Marcellusi, PLC Paola Raimondo, C Galeone. Time to market access in Italia: durata del processo di P&R per i farmaci per le malattie rare. Glob. 2023;10: 79\u201388. https:\/\/doi.org\/10.33393\/grhta.2023.2610.","DOI":"10.33393\/grhta.2023.2610"},{"issue":"1","key":"683_CR33","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.healthpol.2014.03.002","volume":"117","author":"G Fattore","year":"2014","unstructured":"Fattore G, Petrarca G, Torbica A. Traveling for care: inter-regional mobility for aortic valve substitution in Italy. Health Policy (New York). 2014;117(1):90\u20137. https:\/\/doi.org\/10.1016\/j.healthpol.2014.03.002.","journal-title":"Health Policy (New York)."},{"key":"683_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02767-w","author":"BL Levine","year":"2024","unstructured":"Levine BL, et al. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat Med. 2024. https:\/\/doi.org\/10.1038\/s41591-023-02767-w.","journal-title":"Nat Med"},{"key":"683_CR35","unstructured":"Ghilardi G, et al. T-cell lymphoma and secondary primary malignancy risk after commercial CAR T-cell therapy. Nat Med. 2024."},{"issue":"11","key":"683_CR36","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.18609\/cgti.2018.105","volume":"4","author":"A Bersenev","year":"2018","unstructured":"Bersenev A, Kili S. Management of \u2018out of specification\u2019 commercial autologous CAR-T cell products. Cell Gene Ther Insights. 2018;4(11):1051\u20138. https:\/\/doi.org\/10.18609\/cgti.2018.105.","journal-title":"Cell Gene Ther Insights"},{"issue":"September","key":"683_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/frtra.2023.1238535","volume":"2","author":"M Shah","year":"2023","unstructured":"Shah M, Krull A, Odonnell L, de Lima MJ, Bezerra E. Promises and challenges of a decentralized CAR T-cell manufacturing model. Front Transplant. 2023;2(September):1\u20139. https:\/\/doi.org\/10.3389\/frtra.2023.1238535.","journal-title":"Front Transplant"},{"key":"683_CR38","unstructured":"Bristol Myers hits CAR-T manufacturing bottleneck as Abecma demand outstrips supply | Fierce Pharma. https:\/\/www.fiercepharma.com\/manufacturing\/bristol-myers-hits-car-t-manufacturing-bottleneck-as-abecma-demand-outstrips-supply (Accessed Feb. 09, 2024)."},{"key":"683_CR39","unstructured":"Cancer center leaders lay bare CAR-T makers\u2019 struggles. https:\/\/www.fiercepharma.com\/pharma\/johnson-johnson-bristol-myers-kite-pharma-car-t-cell-therapy-struggle-sloan-kettering (Accessed Feb. 09, 2024)."},{"key":"683_CR40","unstructured":"J&J shelves Carvykti\u2019s UK launch amid manufacturing shortfalls. https:\/\/www.fiercepharma.com\/pharma\/johnson-johnson-scraps-carvykti-launch-plan-uk-car-t-manufacturing-remains-lacking (Accessed Feb. 09, 2024)."},{"issue":"2","key":"683_CR41","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3324\/haematol.2019.229781","volume":"105","author":"I Yakoub-Agha","year":"2020","unstructured":"Yakoub-Agha I, et al. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica. 2020;105(2):297\u2013316. https:\/\/doi.org\/10.3324\/haematol.2019.229781.","journal-title":"Haematologica"},{"issue":"June","key":"683_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2022.915342","volume":"13","author":"C Jommi","year":"2022","unstructured":"Jommi C, Bramanti S, Pani M, Ghirardini A, Santoro A. CAR T-cell therapies in italy: patient access barriers and recommendations for health system solutions. Front Pharmacol. 2022;13(June):1\u201311. https:\/\/doi.org\/10.3389\/fphar.2022.915342.","journal-title":"Front Pharmacol"},{"key":"683_CR43","unstructured":"Sesto Report Italiano sulle Advanced Therapy Medicinal Products. 2023. https:\/\/www.atmpforum.com\/report\/."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-024-00683-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-024-00683-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-024-00683-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T19:04:42Z","timestamp":1730487882000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-024-00683-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,15]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["683"],"URL":"https:\/\/doi.org\/10.1007\/s40259-024-00683-0","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,15]]},"assertion":[{"value":"16 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Declarations"}},{"value":"This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"None declared.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"F.T. and P.R.d.V.C.: study design, data interpretation, writing; P.R.d.V.C., A.E., M.L. and A.L.G. data collection, analysis and interpretation; P.R.d.V.C., M.L. and A.E.: manuscript drafting; F.T.: team supervision and manuscript editing. All authors read and approved the final manuscript and declare no conflicts of interest. The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of their institutional affiliation.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contribution"}}]}}